Related Experiment Video
Updated: Jun 11, 2025
The Establishment and Utilization of Patient Derived Xenograft Models of Central Nervous System Metastasis
Published on: May 7, 2021
Preclinical evaluation of targeted therapies for central nervous system metastases
Alexander J Pfeil1,2, Joshua D Hale2, Tiger S Zhang2
1Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Abstract:
The central nervous system (CNS) represents a site of sanctuary for many metastatic tumors when systemic therapies that control the primary tumor cannot effectively penetrate intracranial lesions. Non-small cell lung cancers (NSCLCs) are the most likely of all neoplasms to metastasize to the brain, with up to 60% of patients developing CNS metastases during the disease process. Targeted therapies such as tyrosine kinase inhibitors (TKIs) have helped reduce lung cancer mortality but vary considerably in their capacity to control CNS metastases. The ability of these therapies to effectively target lesions in the CNS depends on several of their pharmacokinetic properties, including blood-brain barrier permeability, affinity for efflux transporters, and binding affinity for both plasma and brain tissue. Despite the existence of numerous preclinical models with which to characterize these properties, many targeted therapies have not been rigorously tested for CNS penetration during the discovery process, whereas some made it through preclinical testing despite poor brain penetration kinetics. Several TKIs have now been engineered with the characteristics of CNS-penetrant drugs, with clinical trials proving these efforts fruitful. This Review outlines the extent and variability of preclinical evidence for the efficacy of NSCLC-targeted therapies, which have been approved by the US Food and Drug Administration (FDA) or are in development, for treating CNS metastases, and how these data correlate with clinical outcomes.
Insights
Targeted therapies for non-small cell lung cancer (NSCLC) show variable effectiveness against brain metastases due to blood-brain barrier penetration challenges. Engineered drugs demonstrate improved CNS efficacy, correlating with positive clinical outcomes.
Area of Science:
- Oncology
- Neuro-oncology
- Pharmacology
Background:
- The central nervous system (CNS) is a sanctuary site for metastatic tumors, particularly non-small cell lung cancer (NSCLC), with up to 60% of patients developing brain metastases.
- Systemic therapies often fail to penetrate intracranial lesions effectively, limiting treatment options for CNS metastases.
Purpose of the Study:
- To review preclinical evidence for the efficacy of FDA-approved or investigational NSCLC-targeted therapies against CNS metastases.
- To analyze how pharmacokinetic properties, such as blood-brain barrier permeability, influence the CNS efficacy of these targeted therapies.
- To correlate preclinical data with clinical outcomes for NSCLC patients with brain metastases.
Main Methods:
- Evaluation of preclinical data on CNS penetration and efficacy of NSCLC-targeted therapies.
- Analysis of pharmacokinetic properties including blood-brain barrier permeability and transporter affinity.
- Correlation of preclinical findings with clinical trial results and patient outcomes.
Main Results:
- Significant variability exists in the capacity of tyrosine kinase inhibitors (TKIs) to control CNS metastases.
- Many targeted therapies lack rigorous CNS penetration testing during discovery, despite preclinical models being available.
- Engineered TKIs with improved CNS penetration characteristics have shown promising clinical trial results.
Conclusions:
- Pharmacokinetic properties are critical for the CNS efficacy of targeted NSCLC therapies.
- Preclinical assessment of CNS penetration is essential for developing effective treatments for brain metastases.
- Recent advancements in engineering CNS-penetrant TKIs offer improved therapeutic options for NSCLC patients with brain metastases.
